Accredited Investor? We Have a Deal Available Right Now! Click Here to Schedule a Call and Get Full Access

FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 11/2023 published



FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 11/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of November 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 8,390m
  • Biotech received 41% of the total investment volume (-1% compared to the previous month)
  • Oncology dominates as the top indication in Biotech
  • VectorY Therapeutics (Netherlands) has the highest transaction volume of EUR 129m in November, followed by EyeBio (United Kingdom) EUR 122m and NMD Pharma (Denmark) EUR 75m
  • The EIC Fund (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Forbion (Netherlands) and Jeito (France)
  • Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)

To access the full report, please click here.

By Mathias Klozenbücher,  Johannes Link and Marco Buonafede-Bennardo.




Source link

Related Articles

Article